Reducing Harms Associated with Substance Use Through Syringe Services Programs

Syringe Services Programs (SSP)

A Syringe Services Program (SSP) provides services to reduce the harms associated with drug use, and prevent HIV and viral hepatitis infections.



HIV and hepatitis C prevention, testing, and linkage to care

MDH-funded SSPs provide:



Education and tools to prevent overdose, including safer use practices and drug testing supplies



Sharps containers and safe disposal of used syringes



Referrals to medical, mental, and sexual health services



Naloxone kit distribution, training, and education




Sterile syringes and safer use supplies at no cost



Referrals to substance use disorder treatment & recovery supports

The Need in Minnesota

- In 2019, nearly 14,000
 Minnesotans were
 admitted to substance
 use disorder treatment
 for injection drug use —
 a 330% increase since
 2009.
- The majority of new hepatitis C cases are related to injection drug
- There were 262
 new cases of HIV in
 Minnesota in 2022,
 13% of which reported
 injection drug use.



Source: Minnesota Department of Human Services, Behavioral Health Division (BHD), Drug and Alcohol Abuse Normative Evaluation System (DAANES), April 23, 2020.

Syringe Services Programs Benefits

Syringe services programs effectively address many of the concerns related to drug use.



Reduce needle-stick injuries

Communities with access to SSPs experience fewer improperly discarded syringes. In 2022, MDH-funded SSPs took in **1,128,137 used syringes**.

One in three officers are stuck with a needle during their career and in areas with active SSPs, law enforcement officers are 66% less likely to experience a needle-stick injury.



Reduce cases of HIV and hepatitis C infections

When people who inject drugs do not have access to a sterile syringe every time they use, they are at increased risk for acquiring or transmitting HIV, HCV, or other infections.

SSPs are associated with an estimated 50% reduction in new cases of HIV and HCV. In 2022, MDH-funded SSPs distributed 1,710,511 sterile syringes and conducted 694 HIV tests and 408 HCV tests.



Reduce drug overdose deaths

In 2021, 1,286 Minnesotans died of a drug overdose - a 20% increase from 2020. SSPs teach people who use drugs how to respond to an overdose using naloxone, as well as how to prevent overdoses through safer use practices.

In 2022, MDH-funded SSPs distributed approximately **68,480** doses of naloxone, and participants reported reversing nearly 1,200 overdoses with naloxone acquired at an SSP. Research shows that SSPs do not cause any increase in drug use.



Reduce infectious disease treatment costs

Given the costs of treatment, SSPs can be cost-saving interventions.

The average 12-week treatment cost for hepatitis C is \$84,000. The estimated lifetime cost of treating one person living with HIV is \$379,668 (in 2010 dollars). One SSP with an annual budget of \$500,000 would only need to prevent three new cases of HIV to be costsaving.



Increased access to treatment

SSPs meet people where they're at, providing a safe place to connect with services.

When someone has access to an SSP, they are five times more likely to enter treatment for substance use disorder, are more likely to reduce their drug use or stop using, and are more likely to access other medical services. In 2022, MDH-funded SSPs served approximately **12,000 unique clients**.

Syringe access

Minnesota legislation allows any pharmacy to sell syringes without a prescription. Although every community could benefit from a syringe services program (SSP), there are still a small number of SSPs, mostly in the Twin Cities. Pharmacy syringe access allows statewide access to sterile syringes.

MDH-funded SSPS

- Harm Reduction Sisters
- Native American Community Clinic
- NorthPoint Health and Wellness
- Ramsey County Clinic 555
- Rural AIDS Action Network (RAAN), Duluth
- Southside Harm Reduction Services

References

- www.cdc.gov/ssp/syringe-services-programssummary.html.
- 2. 2022 MDH Syringe Services Programs Grantee Progress Reports.
- Groseclose, S. L., Weinstein, B., Jones, T. S., Valleroy, L. A., Fehrs, L. J., and Kassler, W. , "Impact of increased legal access to needles and syringes on practices of injecting drug users and police officers — Connecticut, 1992–1993," Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, vol. 10, no. 1, 1995, p. 82–89.
- Retrovirology, vol. 10, no. 1, 1995, p. 82–89.

 4. Minnesota Department of Health HIV/AIDS Statistics (www.health.state.mn.us/diseases/hiv/stats/index.html).
- Minnesota Department of Health Opioids Data (www.health.state.mn.us/communities/opioids/data/ index.html).
- Institute of Medicine. 2006. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, D.C.: The National Academies Press
- Schumock, G. T., Li, E. C., Suda, K. J., Wiest, M. D., Stubbings, J., Matusiak, L. M., Hunkler, R. J., Vermeulen, L. C. "National trends in prescription drug expenditures and projections for 2015," American Journal of Health-System Pharmacy. 2015 May 1;72(9): 717-736.
- Schackman, B. R., Gebo, K. A., Walensky, R. P., Losina, E., Muccio, T., Sax, P. E., Weinstein, M. C., Seage, G. R. 3rd, Moore, R. D., Freedberg, K. A. "The lifetime cost of current human immunodeficiency virus care in the United States. Med Care." 2006 Nov:44(11):990 997.
- United States. Med Care." 2006 Nov.;44(11):990 997.
 Des Jarlais, D. C., Feelemyer, J., McKnight, C. et al. "Is your syringe services program cost-saving to society? A methodological case study." Harm Reduct J 18, 126 (2021)
- Center for Innovative Public Policies. "Needle Exchange Programs: Is Baltimore a Bust?" Tamarac, F. I.: CIPP; April 2001. January 2019.
- 11. Possession and Sale of Hypodermic Syringes and Needles, Minnesota Statutes, section 151.40, subdivision 2 (2023).



Minnesota Department of Health 651-201-5414 or 1-877-676-5414 health.mn.gov

09/2023